Overview
Epidermolytic palmoplantar keratoderma (EPPK), also known as Vörner palmoplantar keratoderma or keratosis palmoplantaris cum degeneratione granulosa, is a hereditary skin disorder characterized by diffuse, thick, yellow hyperkeratosis (thickening of the skin) affecting the palms of the hands and soles of the feet. It is the most common form of diffuse palmoplantar keratoderma. Symptoms typically appear in the first months of life, with well-demarcated thickening of the skin on the palms and soles that may be accompanied by a red border at the margins. The thickened skin can develop painful fissures (cracks), and hyperhidrosis (excessive sweating) of the affected areas is common, which may lead to secondary bacterial or fungal infections and associated malodor. Histologically, the condition is distinguished by epidermolytic hyperkeratosis, a characteristic pattern of degeneration in the upper layers of the epidermis. EPPK is caused by mutations in the KRT9 gene (keratin 9), which encodes a keratin protein expressed specifically in the suprabasal epidermis of palms and soles. Less commonly, mutations in KRT1 (keratin 1) have been associated with this condition, sometimes with mild involvement of skin beyond the palms and soles. The disease follows an autosomal dominant inheritance pattern, meaning a single copy of the altered gene is sufficient to cause the disorder. There is currently no cure for epidermolytic palmoplantar keratoderma. Treatment is symptomatic and focuses on managing the thickened skin. Topical keratolytic agents such as salicylic acid, urea-based creams, and topical retinoids are commonly used to soften and reduce the hyperkeratosis. Mechanical debridement (careful removal of thickened skin) may also be helpful. Oral retinoids such as acitretin may be considered in more severe cases but require careful monitoring due to potential side effects. Management of hyperhidrosis and prevention of secondary infections are also important aspects of care. Regular follow-up with a dermatologist experienced in genodermatoses is recommended.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Epidermolytic palmoplantar keratoderma.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Epidermolytic palmoplantar keratoderma at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Epidermolytic palmoplantar keratoderma.
Community
No community posts yet. Be the first to share your experience with Epidermolytic palmoplantar keratoderma.
Start the conversation →Latest news about Epidermolytic palmoplantar keratoderma
No recent news articles for Epidermolytic palmoplantar keratoderma.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Epidermolytic palmoplantar keratoderma
What is Epidermolytic palmoplantar keratoderma?
Epidermolytic palmoplantar keratoderma (EPPK), also known as Vörner palmoplantar keratoderma or keratosis palmoplantaris cum degeneratione granulosa, is a hereditary skin disorder characterized by diffuse, thick, yellow hyperkeratosis (thickening of the skin) affecting the palms of the hands and soles of the feet. It is the most common form of diffuse palmoplantar keratoderma. Symptoms typically appear in the first months of life, with well-demarcated thickening of the skin on the palms and soles that may be accompanied by a red border at the margins. The thickened skin can develop painful fis
How is Epidermolytic palmoplantar keratoderma inherited?
Epidermolytic palmoplantar keratoderma follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Epidermolytic palmoplantar keratoderma typically begin?
Typical onset of Epidermolytic palmoplantar keratoderma is infantile. Age of onset can vary across affected individuals.
Which specialists treat Epidermolytic palmoplantar keratoderma?
5 specialists and care centers treating Epidermolytic palmoplantar keratoderma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.